Roche at ISTH 2023

World Congress in Fetal Medicine

Visit the Roche booth at ISTH to experience coagulation diagnostic solutions from labs to patients' home

24 - 28 June 2023

Montreal, Canada

Roche at ISTH 2023

As pioneers in the IVD industry, we have been at the forefront of developing innovative solutions that advance patient care in coagulation disorders. At our booth, you will have the opportunity to explore our diagnostic solutions designed for different health care settings: ranging from the laboratory to the patient’s home.

Join us as we showcase our comprehensive range of diagnostic assays, instruments and software, designed to support accurate and timely diagnosis and monitoring. Our team of experts will be on hand to provide in-depth demonstrations using the latest 3D visualisation technology, answer your questions and discuss how our solutions can empower you in delivering optimal patient care.

Come discover why Roche is the trusted partner for coagulation diagnostics.

Highlights from previous ISTH events


Looking back

Roche-sponsored symposium recording

Watch ISTH 2022 Roche Symposium


Tuesday, 12th July 2022
13:15 - 14:30pm BST


Advances in diagnosis and management of bleeding disorders

Bringing scientists and clinicians together


13:15 - 13:20

Welcome and Introduction

Prof. Alok Srivastava, Dr. Annette Bowyer

13:20 - 13:38

Women and girls with haemophilia: global diagnostic and therapeutic challenges

Prof. Cedric Hermans

Prof. Hermans discusses the differences between clotting factor VIII and factor IX deficiencies in female carriers of haemophilia, referred to as women and girls with haemophilia, and their underlying mechanisms. He also addresses the lack of awareness around haemophilia among females and the influence of culture, the impact this has on diagnosis and the need for treatment.

Haemophilia A and B are both rare X-linked, hereditary bleeding disorders, caused by mutations in the genes encoding clotting factor VIII and factor IX, respectively, with the varying disease severity classified according to the level of factor activity. Despite carrier testing and genetic counselling being integrated within haemophilia care, diagnosis and management of haemophilia carriers frequently remains suboptimal with several challenges and unmet needs still present.

13:38 - 13:56

Haemophilia and the impact of result variations when monitoring factor replacement

Prof. Andreas Tiede

Prof. Tiede discusses the history of discrepancies between assays of clotting factor VIII activity, including the introduction of recombinant concentrates, and provides an overview of the mechanisms for these discrepancies. He also discusses the significance and relevance of assay discrepancies in contemporary factor concentrates, including longer-acting molecules and provide guidance for practical solutions within clinical laboratories.

The ability to reliably monitor levels of clotting factor activity is clinically essential to optimise treatment as patient clotting factor activity can change over time. Having accurate and reliable assays can aid in clinical decision-making, e.g. individualising dosing regimens and surgical management, and improved monitoring can increase cost effectiveness.

13:56 - 14:15

Delayed diagnosis of rare bleeding disorders – children and women at risk

Dr. Paula HB Bolton-Maggs

Dr. Bolton-Maggs explores the impact of a delayed diagnosis of rare bleeding disorders, particularly in women, infants and in mobile populations and highlight the problems faced in the management of these patients.

Severe deficiency can present with catastrophic bleeding in infancy. These rare bleeding disorders can also cause serious complications in women, requiring timely care and attention. In addition to menorrhagia, affected females may have an increased risk of other gynaecological conditions; risks of miscarriage, ante-partum and post-partum complications are increased with some coagulation factor deficiencies. However, due to the rarity of some bleeding disorders, and their variable clinical symptoms, it has been difficult to produce evidence-based clinical guidelines.

14:15 - 14:30


Prof. Alok Srivastava, Dr. Annette Bowyer

Meet the speakers

Alok speaker

Alok Srivastava



Alok Srivastava is a Professor of Medicine in the Department of Haematology, and head of the Centre for Stem Cell Research at the Christian Medical College (CMC), Vellore in India.

Dr. Srivastava has been involved with the management of patients with bleeding disorders for over 25 years. His group has worked extensively on developing genetic diagnosis of bleeding disorders and clinical protocols for their management which address the needs in developing countries. Their recent focus has also included assessment of novel therapies in different clinical trials with a major program for developing gene therapy for haemophilia. He leads the World Federation of Hemophilia designated International Hemophilia Training Center at CMC, Vellore. Dr. Srivastava is President of the Indian Association for Haemophilia & Allied Disorders. He is also the chair of the steering committee of the Association for Haemophilia & Allied Disorders – Asia-Pacific. He was the chair of the FVIII/IX subcommittee of the Scientific and Standardization Committee (SSC),

International Society of Thrombosis and Haemostasis (ISTH) from 2006-2010. He was on the board of the WFH from 2002-2014 and served as the Vice-President (Medical) from 2012-2014. He has led the writing group for all three editions of the WFH guidelines for the management of haemophilia .

anette speaker

Annette Bowyer

PhD in Cardiovascular Science


Annette Bowyer is the Scientific Lead for Haemophilia Assays in the Department of Coagulation at Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK, which has been designated an International Haemophilia Training Centre by the World Federation of Haemophilia.

Dr. Bowyer was awarded her PhD in Cardiovascular Science from the University of Sheffield, UK, with a thesis focussing on the laboratory diagnosis of mild haemophilia A, and has more than 20 years’ experience in the diagnosis and monitoring of bleeding disorders. Her current interest is on laboratory issues surrounding treatment products for haemophilia and von Willebrand disease. Dr Bowyer is a member of both the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) Laboratory Working Party and the World Federation of Haemophilia laboratory working party, a fellow of the Institute of Biomedical Science, and a member of the International Society on Thrombosis and Haemostasis and the European Association for Haemophilia and Allied Disorders.

prof. hermanns speaker

Cedric Hermans



Cedric Hermans currently heads the Division of Haematology, the Haemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015. Professor Hermans has (co)-authored more than 300 original articles in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects. He was president of EAHAD and is currently member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal. His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.

andreas tiede speaker

Andreas Tiede

Professor of Haemostasis and Thrombosis


Andreas Tiede is Professor of Haemostasis and Thrombosis, Head of the Haemophilia Care Centre the Central Hematology Laboratory at Hannover Medical School in Hannover, Germany. His main areas of interest for basic and clinical research include congenital and acquired disorders of haemostasis, classical hematology and laboratory hematology. He is Associate Editor of “Annals of Hematology” and “Thrombosis and Haemostasis”.


paula speaker

Paula H.B.Bolton-Maggs 



Paula H.B.Bolton-Maggs was Medical Director of the Serious Hazards of Transfusion (SHOT) national haemovigilance scheme from October 2011 to August 2018, and is currently Honorary Senior Lecturer in the Faculty of Biology, Medicine and Health at Manchester University since 2003.

Dr. Bolton-Maggs has a longstanding interest in haemostasis; most recently she was responsible for collation and analysis of the UK adverse incidents relating to blood transfusion (website She received the Mollison award from the British Blood Transfusion Society in 2018 in recognition of her contribution to haemovigilance,was secretary of the International Haemovigilance Network 2011 to 2018 and received the IHN Medal for her contribution.

Dr. Bolton-Maggs has researched for 25 years especially in the area of factor XI deficiency and has a major interest in rare bleeding disorders. She has taken the lead on and contributed to several national guidelines in this field, published by the British Society for Haematology.


ISTH Roche bibliography download

Roche in Haemostasis


ISTH 2021

Roche-sponsored Virtual Symposium at ISTH 2021

Sunday, 18th of July 2021

This session will take you from strategies and gaps in DOAC monitoring and solutions and challenges with the new Contact Pathway Inhibitors; to the gut microbiota, its effect on the hepatic endothelium and the emerging evidence of its link to the development of cardiovascular diseases and arterial thrombosis; as well as to the latest data of the ACTIV-4 trial and the efficacy of various anticoagulation strategies in COVID-19 thrombosis prevention and thromboinflammation management.


Sunday, 18th of July 2021

From Basic Research to Clinical Data: the Future of Patient Management

Welcome and Introduction
Chair: Marcel Levi, London/UK

Measurement of Direct Oral Anticoagulants and Contact Pathway Inhibitors
Speaker: Jonathan Douxfils, Namur/Belgium

The gut Microbiota – an Actuating Variable in Arterial Thrombosis
Speaker: Christoph Reinhardt, Mainz/Germany

Thromboinflammation & Current RCT Data – are we Ready for the Future?
Speaker: Jean.M Connors, Boston/USA

Q&A, Session close
Chair: Marcel Levi, London/UK & all speakers

Meet the speakers

James Januzzi

Marcel Levi

London, UK


Prof. of Medicine, MD, PhD, FRCP


Marcel Levi is Professor of Medicine at University College London Hospitals and a practicing physician in acute medicine and hematology. Previously he was Dean of the Faculty of Medicine of the University of Amsterdam and Chief Executive of the Academic Medical Center in Amsterdam. He has published over 700 articles in scientific journals and has received a number of international research awards. He is currently chairman of the scientific board of several national charities, a board member of the National Cancer Institute and a member of the Royal Netherlands Academy of Science and Fellow of the Royal College of Physicians.

James Januzzi

Jonathan Douxfils

Namur, Belgium


PharmD, PhD


Prof Jonathan Douxfils is an academic at the University of Namur, Belgium, whose research has played a leading role in establishing well-recognized guidelines for the laboratory measurement of direct oral anticoagulants. He is also a pharmacovigilance expert at the European Medicines Agency, co-chairmen of the SSC Control of Anticoagulation at the International Society on Thrombosis and Haemostasis, a Member Expert Team Haemostasis Diagnostics at ECAT, and co-founder/CEO of the contract research organization, QUALIblood. Recently, he has received the Eberhard F. Mammen Young Investigator Award and was nominated as “Namurois of Year”, category Sciences, for his scientific engagement and discovery.

James Januzzi

Christoph Reinhardt

Mainz, Germany


Assoc. Professor


Christoph Reinhardt is an Associate Professor of Experimental Hemostasis and Gnotobiotics at the Center for Thrombosis and Hemostasis at University Medical Center, Johannes Gutenberg-University of Mainz, Germany. As part of his junior professorship, his research team established germ-free mouse isolator technology used to investigate molecular and cellular mechanisms acting on the vascular system through the microbial colonization of body surfaces, influencing the development of cardiovascular diseases. During his career, Assoc Prof Reinhardt has co-authored numerous scientific articles published in respected journals including Blood, Journal of Thrombosis and Haemostasis, Nature Medicine and Cell.

James Januzzi

Jean.M Connors

Boston, USA




Jean Connors is Medical Director of the Anticoagulation Management Service at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and an Associate Professor of Medicine at Harvard Medical School, Boston, MA. After receiving her MD from Johns Hopkins University, Baltimore, she completed a residency in internal medicine at Beth Israel Deaconess Medical Center, Boston, and fellowships in transfusion medicine and hematology/oncology from Brigham and Women’s Hospital. Dr Connors is an Associate Editor for the Journal of Thrombosis and Haemostasis and is involved in many professional societies. She is currently the PI for a NIH/NHLBI antithrombotics trial in COVID-19-positive outpatients.

ISTH Recording